To date the development of CSF biomarkers based on neuropathological profiles can help to discriminate FTD from other types of dementia [66–68], even if Tau/Ab42 ratio can distinguish AD from FTD with a diagnostic accuracy of only 70% for the bvFTD forms [69]. This evidence concerns the gene MAPT and frontotemporal dementia.